A Message from Yukiko Hashitera, President of R-Tech Ueno:

R-Tech Ueno was born out of the research on prostaglandin metabolite conducted by founder Dr. Ryuji Ueno, and has grown into a medical technology company with an innovative market-leading product for the treatment of glaucoma and ocular hypertension, Rescula® Eye Drops. Rescula® is now being used by more than five hundred thousand patients worldwide and its total sales is up to one hundred billion yen.

In April 2006, the second product, chronic idiopathic constipation drug AMITIZA® was launched in the US. AMITIZA® was developed by Sucampo Pharmaceuticals, Inc. (Bethesda, Maryland, US) and we have participated in its developmental efforts. We have the exclusive right to manufacture and supply of the drug. The Research & Development Division was established in April 2006 to further the development of drugs that through new mechanism of action will target ophthalmic diseases for which there are not yet any known effective pharmaceutical treatments.

Our mission is to efficiently develop and expeditiously deliver first-rate drug products. In order to achieve this mission, we have adopted the following tenets:

1. Keeping in mind the venture spirit, we seek to conduct a speedy development of drugs based on a wellspring of revolutionary ideas.
2. Utilizing our abundant knowledge in the field of compound chemistry and manufacturing know-how, we seek to build a manufacturing division high in supplemental value.
3. By communicating the latest news from ophthalmologists’ patients and our own company to the medical community, we wish to improve people’s health and quality of life.
4. The pharmaceutical business is changing dynamically and has surpassed all borders. By maintaining close contact with companies and research institutions abroad, we seek to come forth as a business with a keen global perspective.
5. With a strong personnel system, we will secure an excellent staff and aim to be a company overflowing from the strength of a group of passionate professionals who number few in the world.

Through efficient and rapid pharmaceutical development based on our own innovative ideas, R-Tech Ueno intends to contribute to the medical progress and thereby increase our company value.

R-Tech Ueno Corporation
President
Yukiko Hashitera